Group 1 - China’s Ministry of Commerce reported that during recent negotiations, both China and the U.S. reached preliminary consensus on several issues, indicating a constructive dialogue [2] - The Financial Regulatory Bureau emphasized the need to effectively manage risks in key areas and support the resolution of debt risks for financing platforms, while preventing illegal financial activities [2] - The Ministry of Industry and Information Technology highlighted the importance of optimizing and upgrading the industrial system, promoting new technologies, and developing emerging industries such as integrated circuits and aerospace [3] Group 2 - Meta plans to invest up to $27 billion in AI company Nebius over the next five years, with Nebius set to provide dedicated computing power starting in 2027 [4] - The recent price fluctuations in major chemical products have not significantly impacted the profitability or gross margins of Sanlianban Sanfangxiang [6] - The methanol market has seen a slight price increase, but Chitianhua has not engaged in any export sales of its methanol products [7] Group 3 - Xiangyou Technology is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [9] - Huichuang Data plans to distribute a dividend of 3.4 yuan per share and expects a 68.32% year-on-year increase in net profit for 2025 [10] - Jinfang Energy anticipates a 176.06% year-on-year increase in net profit for 2025 and plans to distribute a dividend of 2.5 yuan per share [11]

证券代码：688553 证券简称：汇宇制药 公告编号：2026-015 四川汇宇制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露之日，四川汇宇制药股份有限公司(以下简称"公司")股 东王晓鹏女士持有公司股份数量为 16,698,125 股，占公司总股本的 3.942%； 上述股份来源于公司首次公开发行前取得的股份，且已于 2022 年 10 月 26 日起解除限售并上市流通。 减持计划的主要内容 因自身资金需求，股东王晓鹏女士拟通过集中竞价和大宗交易的方式合计 减持公司股份不超过 12,708,000 股，合计减持比例不超过公司股份总数的 3%。减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 若减持计划实施期间公司有派息、送股、资本公积金转增股本、配股等除 权除息事项，减持股份数将进行相应调整。 | 股东名称 | 王晓鹏 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2026-014 四川汇宇制药股份有限公司 自愿披露注射用卡非佐米获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的公司产品注射用卡非佐米的《药品注册证书》，现将相关情况 公告如下： | 药品名称 | 注射用卡非佐米 | | --- | --- | | 剂型 | 注射剂 | | 规格 | 60mg； 10mg； | | | 30mg； | | 注册分类 | 化学药品4类 | | 药品有效期 | 24个月 | | 上市许可持有人 | 四川汇宇制药股份有限公司 | | 生产企业 | 四川汇宇制药股份有限公司 | | 受理号 | CYHS2301410；CYHS2301411；CYHS2301412； | | 证书编号 | 2026S00651；2026S00652；2026S00653； | | 药品批准文号 | 国药准字 H20263538；国药准字 H2026353 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2026-013 四川汇宇制药股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易主要情况 | | □获取投资收益 | | | --- | --- | --- | | 交易目的 | √套期保值（合约类别：□商品；√外汇；□其他：________） | | | | □其他：________ | | | 外汇业务交 | 包括但不限于远期结售汇、外汇远期、外汇掉期、外汇期权、 | | | 易品种 | 利率互换、利率掉期、利率期权等外汇衍生产品或产品组合。 | | | | 预计动用的交易保证金和权利金 | 10,000 | | 交易金额 | 上限（单位：万元） | | | | 预计任一交易日持有的最高合约 | 100,000 | | | 价值（单位：万元） | | | 资金来源 | √自有资金 □借贷资金 □其他：___ | | | 交易期限 | 2026年3月10日至2027年3月10日 | | 已履行及拟履行的审议程 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2026-012 四川汇宇制药股份有限公司 2025 年度业绩快报更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）董事会于2026年2月28日 在《证券时报》《上海证券报》和上海证券交易所网站（http://www.sse.com.cn） 披露了公司2025年年度业绩快报。现对相关内容修正如下，财务数据未经会计师 事务所审计，具体以公司披露的2025年年度的定期报告为准，提请投资者注意投 资风险。 一、修正前后的影响经营业绩的主要因素 更正后： 影响报告期业绩的主要因素： 报告期内，集采政策持续深化，公司对国家集中带量采购政策积极贯彻执行， 相关产品价格、利润下降，对公司业绩产生影响。 报告期内，公司被投资企业浙江同源康医药股份有限公司在香港交易所上市 （证券代码为02410.HK），公司直接持有的其股权在报告期内确认公允价值变 动收益为-1.73亿元。 1 除上述更正内容外，原公告其他内容不变，由此给投资者带来的不 ...

Group 1 - The company, Huiyu Pharmaceutical, reported a total operating revenue of 998.145 million yuan for the fiscal year 2025, representing a year-on-year decline of 8.79% [2] - The net profit attributable to the parent company's shareholders for the same period was -24.2002 million yuan [2]

Financial Performance - Total operating revenue for 2025 was RMB 998.15 million, a decrease of 8.79% compared to the previous year[3] - Operating profit was RMB -65.05 million, down 118.67% year-over-year[3] - Total profit amounted to RMB -63.13 million, reflecting a decline of 118.05% from the prior year[3] - Net profit attributable to shareholders of the parent company was RMB -24.20 million, a decrease of 107.44% compared to the previous year[3] - Basic earnings per share were RMB -0.06, down 107.79% year-over-year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 5,021.61 million, a decrease of 2.79% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was RMB 3,758.96 million, down 5.53% from the beginning of the period[3] Performance Decline Factors - The decline in performance was primarily due to the implementation of centralized procurement policies, leading to reduced product prices and profits[6] Investment Gains - The company recognized a fair value change gain of RMB 173 million from its investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which was listed on the Hong Kong Stock Exchange during the reporting period[7] Financial Data Disclaimer - The company cautions investors that the financial data presented is preliminary and subject to final audit[10]

Market Performance - The pharmaceutical sector increased by 0.84% on February 25, 2025, outperforming the CSI 300 index by 0.24 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, other biological products (+2.39%), hospitals (+2.04%), and medical consumables (+1.58%) showed the best performance, while offline pharmacies (+0.32%), in vitro diagnostics (+0.33%), and medical research outsourcing (+0.34%) lagged behind [1] - Top three gainers in individual stocks were Changchun High-tech (+10.00%), Aidi Te (+9.03%), and Changshan Pharmaceutical (+8.87%); top three losers were Frontier Biotech (-4.09%), Baile Tianheng (-3.62%), and Shuoshi Biotech (-2.97%) [1] Industry News - Immedica announced that the FDA has accelerated the approval of Loargys for the treatment of hyperargininemia in patients aged 2 years and older with arginase 1 deficiency (ARG1-D), based on positive results from the Phase 3 PEACE trial [2] - The trial showed that the geometric mean of plasma arginine (pArg) in patients treated with Loargys decreased significantly from 354.0 μmol/L to 86.4 μmol/L by week 24 [2] - Loargys is a recombinant human arginase that can rapidly and sustainably lower plasma arginine and its toxic metabolites while improving clinical symptoms; it has already been approved in the EU and the UK [2] Company News - Sino Medical (688108) reported a revenue of 525 million yuan for 2025, a year-on-year increase of 14.53%, with a net profit attributable to shareholders of 47 million yuan, up 3057.05%, and a net profit of 34 million yuan after deducting non-recurring items, up 293.82% [3] - United Imaging (688271) announced a revenue of 13.821 billion yuan for 2025, a 34.18% increase year-on-year, with a net profit of 1.888 billion yuan, up 49.60%, and a net profit of 1.788 billion yuan after deducting non-recurring items, up 77.01% [3] - Huyou Pharmaceutical (688553) received notification from the FDA that its new drug applications for etoposide injection and fluorouracil injection have been approved, facilitating the company's expansion into the U.S. market [3] - Aibo Medical (688050) announced plans to acquire 68.31% of Demai Medical for 683 million yuan, with Demai Medical being a leading company in sports medicine; this acquisition will make it a subsidiary of Aibo Medical [3]

Core Viewpoint - Recently, Huiyu Pharmaceutical announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its New Drug Applications (NDA) for Etoposide Injection and Fluorouracil Injection have been approved, allowing the company to produce and sell these products in the U.S. market through overseas partners [1] Group 1 - The FDA approval will help the company expand its sales in the U.S. market, strengthen its product supply chain, and enrich its product portfolio [1] - The approval lays a foundation for the sustainable development of the company's international market [1] - Although the company has begun preparations for the initial sales launch, there is significant uncertainty regarding future revenue due to the non-uniqueness of the products and competition from similar products [1]

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]